BioStock: Continued focus on new licensing deals for CombiGene

CombiGene has published its interim report for the second quarter and substantial emphasis is on the new agreement with Spark concerning the epilepsy project CG01. The company is now focusing on finding a new partner for the project’s continued development, while striving to identify new academic collaborations or licensing deals.
– During the autumn, we will have access to important data from Spark, and then we can establish the strategy for the epilepsy project CG01, says CEO Peter Ekolind to BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/08/continued-focus-on-new-licensing-deals-for-combigene/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/